vs
Side-by-side financial comparison of CIVISTA BANCSHARES, INC. (CIVB) and 4D Molecular Therapeutics, Inc. (FDMT). Click either name above to swap in a different company.
4D Molecular Therapeutics, Inc. is the larger business by last-quarter revenue ($85.1M vs $47.3M, roughly 1.8× CIVISTA BANCSHARES, INC.). CIVISTA BANCSHARES, INC. runs the higher net margin — 31.7% vs 22.8%, a 8.9% gap on every dollar of revenue. Over the past eight quarters, 4D Molecular Therapeutics, Inc.'s revenue compounded faster (5412.6% CAGR vs 11.3%).
Civista Bancshares, Inc. is a US-based bank holding company operating primarily across the Midwest region. It provides a full suite of personal and commercial banking services including deposit accounts, mortgage, consumer and commercial lending products, as well as wealth management solutions, serving retail consumers, small and medium-sized local businesses and community client segments.
4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.
CIVB vs FDMT — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $47.3M | $85.1M |
| Net Profit | $15.0M | $19.4M |
| Gross Margin | — | — |
| Operating Margin | — | 17.3% |
| Net Margin | 31.7% | 22.8% |
| Revenue YoY | — | 8508900.0% |
| Net Profit YoY | 47.4% | 139.1% |
| EPS (diluted) | $0.72 | $0.43 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $47.3M | — | ||
| Q4 25 | $46.3M | $85.1M | ||
| Q3 25 | $44.2M | $90.0K | ||
| Q2 25 | $41.4M | $15.0K | ||
| Q1 25 | $40.6M | $14.0K | ||
| Q4 24 | $40.4M | $1.0K | ||
| Q3 24 | $39.3M | $3.0K | ||
| Q2 24 | $38.1M | $5.0K |
| Q1 26 | $15.0M | — | ||
| Q4 25 | — | $19.4M | ||
| Q3 25 | $12.8M | $-56.9M | ||
| Q2 25 | $11.0M | $-54.7M | ||
| Q1 25 | $10.2M | $-48.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | $8.4M | $-43.8M | ||
| Q2 24 | $7.1M | $-35.0M |
| Q1 26 | — | — | ||
| Q4 25 | 31.8% | 17.3% | ||
| Q3 25 | 35.4% | -67983.3% | ||
| Q2 25 | 31.1% | -396373.3% | ||
| Q1 25 | 29.4% | -383007.1% | ||
| Q4 24 | 28.2% | — | ||
| Q3 24 | 25.2% | -1704400.0% | ||
| Q2 24 | 21.2% | -849120.0% |
| Q1 26 | 31.7% | — | ||
| Q4 25 | — | 22.8% | ||
| Q3 25 | 28.9% | -63195.6% | ||
| Q2 25 | 26.6% | -364386.7% | ||
| Q1 25 | 25.0% | -342657.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | 21.3% | -1461433.3% | ||
| Q2 24 | 18.5% | -699060.0% |
| Q1 26 | $0.72 | — | ||
| Q4 25 | $0.59 | $0.43 | ||
| Q3 25 | $0.68 | $-1.01 | ||
| Q2 25 | $0.71 | $-0.98 | ||
| Q1 25 | $0.66 | $-0.86 | ||
| Q4 24 | $0.62 | — | ||
| Q3 24 | $0.53 | $-0.79 | ||
| Q2 24 | $0.45 | $-0.63 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $402.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $553.9M | $505.7M |
| Total Assets | $4.3B | $566.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $402.7M | ||
| Q3 25 | — | $305.1M | ||
| Q2 25 | — | $293.2M | ||
| Q1 25 | — | $321.4M | ||
| Q4 24 | — | $424.9M | ||
| Q3 24 | — | $501.9M | ||
| Q2 24 | — | $541.9M |
| Q1 26 | $553.9M | — | ||
| Q4 25 | $543.5M | $505.7M | ||
| Q3 25 | $499.0M | $369.0M | ||
| Q2 25 | $404.1M | $420.9M | ||
| Q1 25 | $397.4M | $469.7M | ||
| Q4 24 | $388.5M | $510.6M | ||
| Q3 24 | $394.4M | $552.9M | ||
| Q2 24 | $373.8M | $588.3M |
| Q1 26 | $4.3B | — | ||
| Q4 25 | $4.3B | $566.7M | ||
| Q3 25 | $4.1B | $424.0M | ||
| Q2 25 | $4.2B | $473.6M | ||
| Q1 25 | $4.1B | $515.7M | ||
| Q4 24 | $4.1B | $560.4M | ||
| Q3 24 | $4.1B | $604.0M | ||
| Q2 24 | $4.0B | $620.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $28.6M |
| Free Cash FlowOCF − Capex | — | $28.5M |
| FCF MarginFCF / Revenue | — | 33.5% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | — | 1.47× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-109.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $43.3M | $28.6M | ||
| Q3 25 | $19.0M | $-46.5M | ||
| Q2 25 | $11.1M | $-43.4M | ||
| Q1 25 | $3.6M | $-47.8M | ||
| Q4 24 | $48.2M | $-134.6M | ||
| Q3 24 | $12.9M | $-29.4M | ||
| Q2 24 | $12.2M | $-30.2M |
| Q1 26 | — | — | ||
| Q4 25 | $42.1M | $28.5M | ||
| Q3 25 | — | $-46.6M | ||
| Q2 25 | — | $-43.4M | ||
| Q1 25 | $3.5M | $-48.4M | ||
| Q4 24 | $44.1M | $-138.4M | ||
| Q3 24 | — | $-31.2M | ||
| Q2 24 | — | $-30.6M |
| Q1 26 | — | — | ||
| Q4 25 | 90.9% | 33.5% | ||
| Q3 25 | — | -51765.6% | ||
| Q2 25 | — | -289620.0% | ||
| Q1 25 | 8.5% | -345635.7% | ||
| Q4 24 | 109.1% | -13837100.0% | ||
| Q3 24 | — | -1038966.7% | ||
| Q2 24 | — | -611840.0% |
| Q1 26 | — | — | ||
| Q4 25 | 2.5% | 0.1% | ||
| Q3 25 | — | 101.1% | ||
| Q2 25 | — | 440.0% | ||
| Q1 25 | 0.4% | 4507.1% | ||
| Q4 24 | 10.4% | 378600.0% | ||
| Q3 24 | — | 59266.7% | ||
| Q2 24 | — | 6980.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.47× | ||
| Q3 25 | 1.49× | — | ||
| Q2 25 | 1.01× | — | ||
| Q1 25 | 0.36× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.54× | — | ||
| Q2 24 | 1.73× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CIVB
| Net Interest Income | $37.8M | 80% |
| Noninterest Income | $9.4M | 20% |
FDMT
Segment breakdown not available.
